Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Scientists discover potential drug compounds that target common type of liver cancer

Scientists discover potential drug compounds that target common type of liver cancer

Scientists modify approved cancer drug to develop new antibiotic

Scientists modify approved cancer drug to develop new antibiotic

Experimental drug better for repeat kidney cancer patients than FDA-approved equivalent

Experimental drug better for repeat kidney cancer patients than FDA-approved equivalent

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy improves survival in patients with hepatocellular carcinoma

Study confirms effectiveness of a combination therapy for advanced liver cancer

Study confirms effectiveness of a combination therapy for advanced liver cancer

Repurposing drugs to outsmart cancers

Repurposing drugs to outsmart cancers

Platinum nanoparticles show selective toxicity against liver cancer cells

Platinum nanoparticles show selective toxicity against liver cancer cells

Physicians more likely to prescribe drugs of manufacturers who paid them money

Physicians more likely to prescribe drugs of manufacturers who paid them money

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Scientists develop novel peptide drug that could potentially stop development of liver cancer

Scientists develop novel peptide drug that could potentially stop development of liver cancer

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.